{"id":3116,"date":"2017-01-30T01:08:49","date_gmt":"2017-01-30T06:08:49","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=3116"},"modified":"2017-01-30T01:08:49","modified_gmt":"2017-01-30T06:08:49","slug":"txa-709-kid-qidp-block","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2017\/01\/30\/3116\/txa-709-kid-qidp-block\/","title":{"rendered":"TXA-709 –\u00a0 New Kid on the Block"},"content":{"rendered":"

\"\"<\/a><\/p>\n

When searching for FtsZ inhibitors on PubMed, there are 187 hits. When narrowing down the search looking for clinical trials only, there are none.<\/p>\n

Taxis Pharmaceuticals obtained QIDP status for its candidate drug TXA-709 in late 2016 and it is still in preclinical testing. The drug\u2019s target, bacterial replication machinery that forms the Z-ring, is novel and has real potential as all bacteria replicate by binary fission and must generate a cell division wall to split apart. It would seem that attacking this essential step in bacterial cell division would not only arrest bacterial multiplication and achieve bacterial stasis, but also bactericidal activity due to autolysis from frustrated reproduction\u00a0[1]<\/a>. This was already demonstrated in experimental studies with MSSA strains.[2]<\/a><\/p>\n

Key to the potential of any new antibacterial drug is target selection: how essential is this target for replication and critical bacterial life processes? Is it highly conserved and found in most species? Can it be bypassed and have bacteria found alternate routes circumventing a blocked enzymatic step?\u00a0 Are mutations of the target lethal?<\/p>\n

Other questions \u2013 more generic in nature \u2013 deal with accessibility of target for a drug, binding affinity, and the usual defense mechanism of efflux and drug degradation\/inactivation.<\/p>\n

From rudimentary information available on TXA-709, we cannot answer all these questions. We are told that the drug is meant to be developed as an MRSA agent. Our first reaction: Why? Is this the only pathogen susceptible? Are we dealing here again with a very narrow-spectrum drug, the likes and fates of which are not so promising? For Gram-positives, associations with FabI inhibitors resurface, for Gram-negatives, flash-backs of LpxC and POL-7080.<\/p>\n

Regarding TXA-709 specifically, the overarching question is: do we really need another MRSA drug with a very narrow spectrum in ABSSSI and maybe in an additional application?<\/p>\n

The answer is an unquestionable and unconditional YES, WE DO. The recent batch of approved anti-staph and anti-MRSA drugs are all of the same mold, like glycopeptide structures telavancin, oritavancin, dalbavancin and daptomycin, and oxazolidinone congeners linezolid and tedizolid. MRSA \u03b2-lactams ceftaroline and ceftibiprole are just that, \u03b2-lactams.<\/p>\n

In addition, we have a few less reliable older stand-bys, TMP\/SMX, tetracyclines and macrolides. There are also some drugs with MRSA activity that are in development and still have to prove their metal. One of them, solithromycin, just hit a slick spot and is currently in intensive care, so to speak.<\/p>\n

Hence, all our workhorse anti-MRSA drugs come from only 3 drug classes. If TXA-709 and its active component, TXA-707, make it to the market as new IV and PO MRSA drugs, we shall be anxious to use them. And so should you. We fully support FDA\u2019s decision to grant QIDP status to this new kid on the block.<\/p>\n

A thumbs-up to TXA-709, and by analogy, to FabI inhibitor Debio-1450 and the peptidomimetic brilacidin, all representing different compounds as far as chemistry and MoA are concerned.<\/p>\n

TXA-709 does not work in Gram-negatives because of efflux.Taxis Pharma is working on specific efflux inhibitors to broaden the spectrum of TXA-709. A reasonable thing to do but don’t hold your breath for one to materialize soon<\/span><\/p>\n<\/div>\n

Not all looks golden for TXA-709, of course. Obviously, it would be nice if activity were broader than just MRSA, including other Gram-positives perhaps or even Gram-negatives. However, enterococci and streptococci were resistant to a TXA-709 analogue studied by Taxis\u00a0[3]<\/a>. Activity against S. epidermidis is useful, activity against B. subtilis not so much\u00a0[4]<\/a>. The company is working on efflux inhibitors as the drug is shuttled out of Gram-negative bacteria rendering it ineffective. A recent publication makes a case for combination therapy against MRSA with cefdinir; this cephalosporin provided synergy and reduced MIC values by a factor of 3.[5]<\/a><\/p>\n

On the positive side, oral and IV formulations both worked well in a peritonitis model, and cytochrome inhibition seems not to occur with TXA-709.<\/p>\n

 <\/p>\n

References
\n<\/strong>[1]<\/a> For a nice and easy explanation of bacterial cell division and the role of FtsZ see: http:\/\/web.expasy.org\/spotlight\/back_issues\/171
\n[2]<\/a> M Kaul. TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Ef\ufb01cacy against Methicillin-Resistant Staphylococcus aureus. AAC 59:4845\u20134855. doi:10.1128\/AAC.00708-15
\n[3]<\/a> M Kaul.\u00a0 Enterococcal and streptococcal resistance to PC190723 and related compounds: Molecular insights from a FtsZ mutational analysis. Biochimie 2013. 95, 10: 1880
\n[4]<\/a> http:\/\/www.slideshare.net\/NhiHin\/ftsz-a-promising-and-novel-antibiotic-target
\n[5]<\/a> M Kaul. Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus. AAC 60:4290 \u20134296. doi:10.1128\/AAC.00613-16.<\/p>\n","protected":false},"excerpt":{"rendered":"

When searching for FtsZ inhibitors on PubMed, there are 187 hits. When narrowing down the search looking for clinical trials only, there are none. Taxis Pharmaceuticals obtained QIDP status for its candidate drug TXA-709 in late 2016 and it is still in preclinical testing. The drug\u2019s target, bacterial replication machinery Continue reading TXA-709 –\u00a0 New Kid on the Block<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":3119,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[19,3,18],"tags":[403,874,1925,828,876,819,229,66,85,228,1929,1826,1927,717,5,1921,1583,72,1928,223,83,1924,1053,1362,1926,234,67,171,1371,462,468,966,1923,7,829,74,263,767,1922,1819,48,86,90],"class_list":["post-3116","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qidp_antibiotic","category-the_news","category-the_viewpoint","tag-antibiotic-blog","tag-brilacidin","tag-cefdinir","tag-ceftaroline","tag-cellceutix","tag-cempra","tag-cubicin","tag-dalbavancin","tag-dalvance","tag-daptomycin","tag-debio-1450","tag-debiopharm","tag-efflux-inhibitor","tag-fabi-inhibitor","tag-fda","tag-ftsz-inhibitor","tag-harald-reinhart","tag-linezolid","tag-lpxc","tag-macrolide","tag-mrsa","tag-mrsa-drugs","tag-mssa","tag-novel-moa","tag-omnicef","tag-orbactiv","tag-oritavancin","tag-pol-7080","tag-qidp","tag-sivextro","tag-solithromycin","tag-synergy","tag-taxis-pharmaceuticals","tag-tedizolid","tag-teflaro","tag-telavancin","tag-tetracycline","tag-tmpsmx","tag-txa-707","tag-txa-709","tag-vancomycin","tag-vibativ","tag-zyvox"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/FtsZ-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-Og","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":2911,"url":"https:\/\/allphasepharma.com\/dir\/2016\/11\/25\/2911\/prospecting-antibiotics\/","url_meta":{"origin":3116,"position":0},"title":"Prospecting for New Antibiotics","author":"Harald","date":"November 25, 2016","format":false,"excerpt":"The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA\u00a0expedited review and more.\u00a0 In addition, FDA made it quite easy to garner the label.\u00a0 As you can see, there is really no downside to\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"engine-qidp-blog","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1800,"url":"https:\/\/allphasepharma.com\/dir\/2015\/08\/01\/1800\/qidp-drugs-4th-edition\/","url_meta":{"origin":3116,"position":1},"title":"QIDP Drugs – 4th Edition","author":"Harald","date":"August 1, 2015","format":false,"excerpt":">>> For the latest QIDP list, please click HERE \u00a0<<< Since our\u00a0last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table\u00a0which includes compound, sponsor\u00a0and development stage (Phase). It also indicates whether a drug has been\u00a0the topic of a\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"QIDP 4th edition","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":3211,"url":"https:\/\/allphasepharma.com\/dir\/2017\/03\/05\/3211\/qidp-liberal-hand-out-fda\/","url_meta":{"origin":3116,"position":2},"title":"QIDP, a Liberal Hand-Out from FDA","author":"Harald","date":"March 5, 2017","format":false,"excerpt":"On our blog site, \u2018QIDP\u2019 stands for \u201cQualified Infectious Diseases Product\u201d but when you look up \u2018QIDP\u2019 on the internet, you will find that it also stands for \u201cQualified Intellectual Disabilities Professional\u201d. Looking at the more recent crop of ID products that garnered QIDP status, you wonder whether there is\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Great-Heist-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Great-Heist-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Great-Heist-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1332,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/28\/1332\/drugs-with-qidp-designation-update-3282015\/","url_meta":{"origin":3116,"position":3},"title":"Drugs with QIDP Designation \u2013 Update 4\/8\/2015","author":"Harald","date":"March 28, 2015","format":false,"excerpt":"For the latest QIDP listing, please click HERE Our latest internet search came up with 37 drugs that garnered QIDP status.\u00a0 They are listed in the Table below (if I missed a compound, please leave a comment!!). \u00a0The\u00a0table is searchable so you should be able to massage the data to\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"APPC + QIDP copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2205,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/23\/2205\/qidp-antibiotics-2015-year-end-update\/","url_meta":{"origin":3116,"position":4},"title":"QIDP Antibiotics – 2015 Year-End Update","author":"Harald","date":"December 23, 2015","format":false,"excerpt":"Here an updated listing of all QIDP drugs we are aware of as of 12\/24\/2015. Today just\u00a0facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are\u00a058 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":2817,"url":"https:\/\/allphasepharma.com\/dir\/2016\/10\/24\/2817\/qidp-drug-update-part-2-categories-of-interest\/","url_meta":{"origin":3116,"position":5},"title":"QIDP Drug Update \u2013 Part 2: \u00a0Categories of Interest","author":"Harald","date":"October 24, 2016","format":false,"excerpt":"According to Janet Woodcock, 63 drugs have been given the \u201cQIDP\u201d designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development.\u00a0 So we are in fairly close agreement. That may seem like an impressive record but it is also\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"qidp-part2-slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=3116"}],"version-history":[{"count":7,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3116\/revisions"}],"predecessor-version":[{"id":3128,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3116\/revisions\/3128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/3119"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=3116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=3116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=3116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}